Biotech startups often struggle to raise funds and scale their innovations. Fortunately, Sofinnova Partners, a leading European life sciences venture capital firm, is changing that. Their latest fund provides essential support and funding to promising biotech companies across Europe.
Sofinnova Biovelocita II Fund Attracts Global Pharma Giants
Sofinnova recently closed its Biovelocita II Fund, securing an impressive €165 million. The fund exceeded expectations, gaining strong backing from global pharmaceutical leaders like Amgen, Bristol Myers Squibb, and Pfizer Ventures.
This milestone demonstrates the growing demand for biotech acceleration. With this fund, Sofinnova expands its footprint beyond Italy, now supporting startups in France, the UK, and Denmark. More European countries will follow soon.
Bridging the Funding Gap in Life Sciences Innovation
Sofinnova Partners began in 1972, founded to create an American-style venture capital model in France. Over the years, the firm has supported groundbreaking research, including Alzheimer’s treatments from BioClec and fibrosis therapies by Forth Therapeutics.
By combining scientific, medical, and business expertise, Sofinnova helps startups grow from seed-stage ideas to fully operational companies. Today, the firm manages more than €4 billion in assets, proving its success in turning startups into global market leaders.
Biovelocita II: Europe’s Largest Biotech Accelerator Fund
Led by seasoned partners Gabriella Camboni, Matthieu Coutet, Alex Leech, and Zhizhong Joel Yao, the Sofinnova Biovelocita II Fund is now Europe’s largest biotech accelerator.
Since launching, the fund has reviewed over 300 biotech projects. It has already invested in startups working on cutting-edge treatments. These include:
- BioClec – Pioneering Alzheimer’s disease therapies.
- Forth Therapeutics – A University of Edinburgh spin-out creating precision fibrosis treatments.
- Signadori Bio – A next-gen cell therapy company developed from research at the Gustave Roussy Institute.
Each investment represents a step forward in addressing critical healthcare challenges.
Pharma Giants Show Confidence in Sofinnova’s Model
The success of Biovelocita II is a clear signal. Pharmaceutical giants see value in partnering with Sofinnova to fuel biotech breakthroughs. Their involvement not only brings capital but also adds strategic industry knowledge.
Graziano Seghezzi, Managing Partner at Sofinnova, shared:
“Following the success of Biovelocita I, we expanded our strategy across Europe. Surpassing our fundraising target shows the market’s appetite for biotech innovation. Together, we’re shaping the future of healthcare.”
Driving Europe’s Biotech Future Forward
Sofinnova’s latest fund cements its leadership in biotech investment. As the European biotech ecosystem grows, Sofinnova’s hands-on approach and strategic partnerships will help promising startups scale faster.
With more projects in the pipeline, the Sofinnova Biovelocita II Fund is set to drive new biotech innovations — creating solutions that could transform patient care across the world.
For more funding news, click here.
